Open-label Multicenter Phase 2 Study Evaluating the Efficacy & Safety of Daratumumab in Pediatric & Young Adult Subjects =1 & =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Brief description of study

If you have been diagnosed with with Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, you may be qualified for this study. The main goal of this study is to see how effective and safe the drug Daratumumab is in pediatric and young adults with Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma.


Clinical Study Identifier: s18-00259
ClinicalTrials.gov Identifier: NCT03384654


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.